Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
Open Access
- 18 September 2021
- journal article
- review article
- Published by Springer Nature in Advances in Therapy
- Vol. 38 (11) , 5452-5464
Abstract
Background In the absence of head-to-head trials, we performed an indirect treatment comparison of the β3-adrenergic agonists vibegron and mirabegron in the treatment of overactive bladder (OAB). Methods PubMed, Embase, and Cochrane Library were searched for articles related to phase 3, double-blind, controlled trials of vibegron 75 mg and mirabegron 25/50 mg in patients with OAB. Efficacy outcomes included change from baseline at weeks 4, 12, and 52 in mean daily number of total urinary incontinence episodes and micturitions and mean volume voided/micturition. Effect size was computed as placebo-subtracted change from baseline (weeks 4, 12) or active control (tolterodine)-subtracted change from baseline (week 52) for each treatment group. Adverse events (AEs) are presented descriptively. Results After removal of duplicates, 49 records were identified, and after screening 9 met inclusion criteria for analysis. Vibegron showed significantly greater reduction in mean daily number of total incontinence episodes than mirabegron 25 mg at week 4, mirabegron 50 mg (weeks 4, 52), and tolterodine (weeks 4, 12) (P < 0.05, each) and significantly greater improvement in volume voided versus mirabegron 25 mg (week 12), mirabegron 50 mg (weeks 12, 52), and tolterodine (week 4) (P < 0.05, each). Confidence intervals of point estimates overlapped zero for all other comparisons of vibegron and mirabegron (25 or 50 mg) or tolterodine, indicating no significant differences between treatments for these time/endpoints. Urinary tract infection, hypertension, and dry mouth were the most commonly occurring AEs for vibegron, mirabegron, and tolterodine, respectively, in the short-term trials; hypertension was the most commonly occurring AE with all three treatments in the long-term trials. Conclusions Vibegron was associated with significant improvement in total incontinence episodes versus mirabegron at 4 and 52 weeks and volume voided at 12 and 52 weeks. Improvement in micturitions was similar between vibegron and mirabegron or tolterodine. Incidence of AEs was generally comparable between vibegron and mirabegron.Keywords
Funding Information
- Urovant Sciences
This publication has 25 references indexed in Scilit:
- Results of a Randomized Phase III Trial of Mirabegron in Patients with Overactive BladderJournal of Urology, 2013
- Randomized Double-blind, Active-controlled Phase 3 Study to Assess 12-Month Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Overactive BladderEuropean Urology, 2013
- Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European–Australian Phase 3 TrialEuropean Urology, 2013
- Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adultsCochrane Database of Systematic Reviews, 2012
- Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU GuidelineJournal of Urology, 2012
- National Community Prevalence of Overactive Bladder in the United States Stratified by Sex and AgeUrology, 2011
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- Number of Daytime Micturitions and Volume Voided per Micturition in the Evaluation of Efficacy of Drugs for Overactive Bladder: Findings from Randomized Clinical TrialsEuropean Urology, 2007
- Effect of (R)-2-(2-Aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} Acetanilide (YM178), a Novel Selective β3-Adrenoceptor Agonist, on Bladder FunctionThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Bladder‐health diaries: an assessment of 3‐day vs 7‐day entriesBJU International, 2005